Chemoembolization for hepatocellular carcinoma

Seminars in Oncology

Volumn 39, Issue 4, 2012, Pages 503-509

  Lencioni, Riccardo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; SORAFENIB; TAMOXIFEN; VASCULOTROPIN;

ACUTE LIVER FAILURE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONFERENCE PAPER; CONSERVATIVE TREATMENT; DISEASE CONTROL; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER PRESERVATION; LIVER TOXICITY; LIVER TRANSPLANTATION; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME;

CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; HUMANS; LIVER NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84864438332     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2012.05.004     Document Type: Conference Paper

References (48)

1. D.M. Parkin, F. Bray, J. Ferlay, P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108
2. A.H. Olsen, D.M. Parkin, P. Sasieni Cancer mortality in the United Kingdom: projections to the year 2025 Br J Cancer 99 2008 1549 1554
3. G.L. Davis, M.J. Alter, H. El-Serag, T. Poynard, L.W. Jennings Aging of the hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression Gastroenterology 138 2010 513 521
4. W.R. Kim, G.J. Gores, J.T. Benson, T.M. Therneau, L.J. Melton 3rd Mortality and hospital utilization for hepatocellular carcinoma in the United States Gastroenterology 129 2005 486 493
5. R.T. Poon, S.T. Fan, I.O. Ng, C.M. Lo, C.L. Liu, J. Wong Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma Cancer 89 2000 500 507
6. A. Cucchetti, F. Piscaglia, E. Caturelli Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population Ann Surg Oncol 16 2009 413 422
7. J.M. Llovet, A.M. Di Bisceglie, J. Bruix; Panel of Experts in HCC-Design Clinical Trials Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 2008 698 711
8. J. Bruix, M. Sherman Management of hepatocellular carcinoma: an update Hepatology 53 2011 1020 1022
9. European Association for the Study of the Liver; European Organization for Research and Treatment of Cancer EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma J Hepatol 56 2012 908 943
10. R. Lencioni Loco-regional treatment of hepatocellular carcinoma Hepatology 52 2010 762 773
11. M. Varela, M.I. Real, M. Burrel Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics J Hepatol 46 2007 474 481
12. J. Lammer, K. Malagari, T. Vogl Prospective randomised study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study Cardiovasc Intervent Radiol 33 2010 41 52
13. T.J. Vogl, J. Lammer, R. Lencioni Liver, gastrointestinal and cardiac toxicity in intermediate hepatocellular carcinoma treated with doxorubicin-eluting bead AJR Am J Roentgenol 197 2011 562 570
14. R. Lencioni Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy Crit Rev Oncol Hematol 2012 [Epub ahead of print]
15. R. Lencioni, L. Crocetti Loco-regional treatment of hepatocellular carcinoma Radiology 262 2012 43 58
16. D.Y. Lin, Y.F. Liaw, T.Y. Lee, C.M. Lai Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma - a randomized controlled trial Gastroenterology 94 1988 453 456
17. G. Pelletier, A. Roche, O. Ink A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma J Hepatol 11 1990 181 184
18. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma N Engl J Med 332 1995 1256 1261
19. J. Bruix, J.M. Llovet, A. Castells Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution Hepatology 27 1998 1578 1583
20. G. Pelletier, M. Ducreux, F. Gay Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial J Hepatol 29 1998 129 134
21. C.M. Lo, H. Ngan, W.K. Tso Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma Hepatology 35 2002 1164 1171
22. J.M. Llovet, M.I. Real, X. Montana Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial Lancet 359 2002 1734 1739
23. J.M. Llovet, J. Bruix Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival Hepatology 37 2003 429 442
24. R.S. Oliveri, J. Wetterslev, C. Gluud Transarterial (chemo) embolisation for unresectable hepatocellular carcinoma Cochrane Database Syst Rev 3 2011 CD004787
25. C.E. Ray, Z.J. Haskal, J.F.H. Geschwind, B.S. Funaki The use of transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: a response to the Cochrane Collaboration Review of 2011 J Vasc Interv Radiol 22 2011 1693 1696
26. A. Forner, J.M. Llovet, J. Bruix Chemoembolization for intermediate HCC: is there proof of survival benefit? J Hepatol 56 2012 9846
27. E.G. Giannini, G. Bodini, M. Corbo Impact of evidence-based medicine on treatment of patients with unresectable hepatocellular carcinoma Aliment Pharmacol Ther 31 2010 493 501
28. J. Raoul, B. Sangro, A. Forner Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization Cancer Treat Rev 37 2011 212 220
29. M.J. Song, C.H. Park, J.D. Kim Drug-eluting bead loaded with doxorubicin versus conventional Lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients Eur J Gastroenterol Hepatol 23 2011 521 527
30. K. Malagari, M. Pomoni, A. Kelekis Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with Beadblock for hepatocellular carcinoma Cardiovasc Intervent Radiol 33 2010 541 551
31. A. Nicolini, L. Martinetti, S. Crespi, M. Maggioni, A. Sangiovanni Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma J Vasc Interv Radiol 21 2010 327 332
32. R. Lencioni, T. de Baere, M. Burrel Transcatheter treatment of hepatocellular carcinoma with doxorubicin-loaded DC Bead (DEBDOX): technical recommendations Cardiovasc Intervent Radiol 2012 [Epub ahead of print]
33. M. Burrel, M. Reig, A. Forner Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolization (TACE) using Drug Eluting Beads Implications for clinical practice and trial design J Hepatol 56 2012 1330 1335
34. P. Therasse, S.G. Arbuck, E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 2000 205 216
35. A. Forner, C. Ayuso, M. Varela Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 115 2009 616 623
36. R. Lencioni, J.M. Llovet Modified RECIST (mRECIST) assessment for hepatocellular carcinoma Semin Liver Dis 30 2010 52 60
37. J. Edeline, E. Boucher, Y. Rolland Comparison of tumor response by response evaluation criteria in solid tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma Cancer 118 2012 147 156
38. R. Gillmore, S. Stuart, A. Kirkwood EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolisation J Hepatol 55 2011 1309 1316
39. J.H. Shim, H.C. Lee, S.O. Kim Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models Radiology 262 2012 708 718
40. H.Y. Woo, J.W. Jang, J.Y. Choi Tumor doubling time after initial response to transarterial chemoembolization in patients with hepatocellular carcinoma Scand J Gastroenterol 45 2010 332 339
41. J.M. Llovet, S. Ricci, V. Mazzaferro Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
42. A.L. Cheng, Y.K. Kang, Z. Chen Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 2009 25 34
43. B. Wang, H. Xu, Z.Q. Gao, H.F. Ning, Y.Q. Sun, G.W. Cao Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization Acta Radiol 49 2008 523 529
44. S. Virmani, T.K. Rhee, R.K. Ryu Comparison of hypoxia-inducible factor-1alpha expression before and after transcatheter arterial embolization in rabbit VX2 liver tumors J Vasc Interv Radiol 19 2008 1483 1489
45. T.M. Pawlik, D.K. Reyes, D. Cosgrove, I.R. Kamel, N. Bhagat, J. Geschwind Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma J Clin Oncol 29 2012 3960 3967
46. R. Lencioni, J.M. Llovet, G. Han Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial J Clin Oncol 30 suppl 4 2012 (abstr LBA154)
47. J.W. Park, Y.H. Koh, H.B. Kim Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma J Hepatol 56 2012 1336 1342
48. R.G. Gish, R. Lencioni, A.M. Di Bisceglie, J.L. Raoul, V. Mazzaferro Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma Expert Rev Gastroenterol Hepatol 6 2012 173 185